Detects mouse IFN-gamma in direct ELISAs. Does not cross-react with rat, cotton rat, human, rhesus macaque, porcine, feline, or canine IFN-gamma.
Monoclonal Hamster IgG Clone # H22
Protein A or G purified from hybridoma culture supernatant
E. coli-derived recombinant mouse IFN-gamma Accession # P01580
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 µm filtered solution in PBS.
<0.10 EU per 1 μg of the antibody by the LAL method.
Measured by its ability to neutralize IFN‑ gamma inhibition of EMCV-induced cytopathy in the L‑929 mouse fibroblast cell line. Schreiber, R. et al. (1985) J. Immunol. 134:1609; Vogel, S. and M. Hogan (1995) in Current Protocols in Immunology. Ciocio, R. (ed); John Wiley & Sons, Inc. p. 6. 9. 1. The Neutralization Dose (ND50) is typically 4-20 ng/mL in the presence of 2.5 ng/mL Recombinant Mouse IFN‑ gamma.
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are
available in the Technical Information section on our website.
IFN-? Inhibition of EMCV-induced Cytopathy and Neutralization by Mouse IFN-? Antibody. Recombinant Mouse IFN-? (Catalog # 485-MI) reduces the Encephalomyocarditis Virus (EMCV)-induced cytopathy in the L-929 mouse fibroblast cell line in a dose-dependent manner (orange line). Inhibition of EMCV activity elicited by Recombinant Mouse IFN-? (2.5 ng/mL) is neutralized (green line) by increasing concentrations of Hamster Anti-Mouse IFN-? Monoclonal Antibody (Catalog # MAB4851). The ND50 is typically 4-20 ng/mL.
IFN-? in Mouse Splenocytes. IFN-? was detected in immersion fixed mouse splenocytes stimulated with calcium ionomycin and PMA (left panel) or unstimulated (right panel) using Hamster Anti-Mouse IFN-? Monoclonal Antibody (Catalog # MAB4851) at 15 µg/mL for 3 hours at room temperature. Cells were stained using an anti-hamster IgG secondary antibody (red) and counterstained with DAPI (blue). Specific staining was localized to cytoplasm. View our protocol for Fluorescent ICC Staining of Non-adherent Cells.
Preparation and Storage
Reconstitute at 0.5 mg/mL in sterile PBS.
The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.
Interferon-gamma (IFN-gamma ), also known as type II or immune interferon, exerts a wide range of immunoregulatory activities and is considered to be the prototype proinflammatory cytokine (1, 2). Mature mouse IFN-gamma exists as a noncovalently linked homodimer of 20‑25 kDa variably glycosylated subunits (3). It shares 86% amino acid sequence identity with rat IFN-gamma and 38%‑44% with bovine, canine, cotton rat, equine, feline, human, porcine, and rhesus IFN-gamma. IFN-gamma dimers bind to IFN-gamma RI (alpha subunits) which then interact with IFN-gamma RII (beta subunits) to form the functional receptor complex of two alpha and two beta subunits. Inclusion of IFN-gamma RII increases the binding affinity for ligand and the efficiency of signal transduction (4, 5). IFN-gamma is produced by a variety of immune cells under inflammatory conditions, notably by T cells and NK cells (6). It plays a key role in host defense by promoting the development and activation of Th1 cells, chemoattraction and activation of monocytes and macrophages, up‑regulation of antigen presentation molecules, and immunoglobulin class switching in B cells. It also exhibits antiviral, antiproliferative, and apoptotic effects (6, 7). In addition, IFN-gamma functions as an anti-inflammatory mediator by promoting the development of regulatory T cells and inhibiting Th17 cell differentiation (8, 9). The pleiotropic effects of IFN-gamma contribute to the development of multiple aspects of atherosclerosis (7).
Billiau, A. and P. Matthys (2009) Cytokine Growth Factor Rev. 20:97.
Pestka, S. et al. (2004) Immunol. Rev. 202:8.
Gray, P.W. and D.V. Goeddel (1983) Proc. Natl. Acad. Sci. 80:5842.
Marsters, S.A. et al. (1995) Proc. Natl. Acad. Sci. 92:5401.
Krause, C.D. et al. (2000) J. Biol. Chem. 275:22995.
Schroder, K. et al. (2004) J. Leukoc. Biol. 75:163.
R&D Systems personnel manually curate a database that contains references using R&D Systems products.
The data collected includes not only links to publications in PubMed,
but also provides information about sample types, species, and experimental conditions.